New York, Feb 6, 2026, 12:50 EST — Regular session
- JNJ shares ticked up roughly 0.2%, hovering around $238.34 by midday
- New Jersey appeals court has blocked Beasley Allen from representing plaintiffs in state talc lawsuits
- FDA issues most serious recall classification for specific CEREPAK detachable coil systems
Johnson & Johnson shares inched higher on Friday, rising roughly 0.2% to $238.34 around midday, having peaked at $240.22 earlier. This kept the stock just above Thursday’s closing price of $237.79.
The latest legal development is significant since talc lawsuits remain a major unresolved issue for the company, despite steady cash flow from its drugs and medical devices divisions. Investors react fast to anything that could change how these cases are handled or settled.
A New Jersey appeals court has blocked plaintiffs’ firm Beasley Allen from representing claimants in a consolidated group of state lawsuits accusing J&J’s baby powder of causing cancer, overturning a lower court’s decision. J&J’s Erik Haas slammed the firm’s actions as an “ethical violation,” warning that “anything less would reward unethical behavior.” Beasley Allen announced plans to appeal to the state Supreme Court. There are over 67,500 related cases pending in federal court and around 3,600 in New Jersey state court. Meanwhile, J&J’s separate effort to disqualify the firm in federal court remains unresolved. Reuters
The U.S. Food and Drug Administration issued a recall notice for certain CEREPAK detachable coil systems used to treat aneurysms. The agency classified it as its most serious recall, warning the devices could cause severe injury or death if used. The recall follows a higher-than-expected failure-to-detach rate, with the FDA reporting four serious injuries and one death as of Oct. 14, 2025.
The broader market lifted. The S&P 500 tracking ETF rose roughly 1.6%, while the Nasdaq 100 tracker gained about 1.8%. That gave a boost to large-cap health stocks, which often act as defensive plays when investors start taking on more risk.
Medtech investors adjusted their outlook after Boston Scientific shares dipped earlier this week, following a miss in its electrophysiology unit — the heart-rhythm device segment. Citi analyst Joanne Wuensch commented that “their worries were not misplaced,” while CEO Michael Mahoney reassured investors the company still aims to “outpace that market growth” in 2026. Reuters
J&J, known for its cardiovascular and other specialty devices, faces a mixed picture. Rival missteps might relieve some pressure in certain areas, yet soft demand or pricing shifts could quickly ripple through the company. Traders are closely tracking if the coil-system recall remains limited to a few products or sparks wider concerns over device quality controls.
Friday’s talc ruling doesn’t offer a straightforward escape. Beasley Allen can still push for relief on appeal, the federal court disqualification motion is still up in the air, and the cancer claims at the core are moving toward trials that could shift sentiment dramatically.
The next hurdle for the stock is staying above the mid-$230s after pushing toward $240. Investors are watching closely for follow-through from the legal news and any fresh FDA moves related to the recall.
Johnson & Johnson announced a quarterly dividend of $1.30 per share, payable March 10. The ex-dividend date is set for Feb. 24, meaning purchases made after that date won’t qualify for the payout.
